AU2009308665B2 - Compositions containing delta-9-THC-amino acid esters and process of preparation - Google Patents
Compositions containing delta-9-THC-amino acid esters and process of preparation Download PDFInfo
- Publication number
- AU2009308665B2 AU2009308665B2 AU2009308665A AU2009308665A AU2009308665B2 AU 2009308665 B2 AU2009308665 B2 AU 2009308665B2 AU 2009308665 A AU2009308665 A AU 2009308665A AU 2009308665 A AU2009308665 A AU 2009308665A AU 2009308665 B2 AU2009308665 B2 AU 2009308665B2
- Authority
- AU
- Australia
- Prior art keywords
- amino acid
- thc
- tetrahydrocannabinol
- derivative
- dcm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 33
- 230000008569 process Effects 0.000 title description 3
- 235000001014 amino acid Nutrition 0.000 claims abstract description 99
- -1 but not limited to Chemical class 0.000 claims abstract description 60
- 150000001413 amino acids Chemical class 0.000 claims abstract description 45
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000004474 valine Substances 0.000 claims abstract description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 10
- 108010077895 Sarcosine Proteins 0.000 claims abstract description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940043230 sarcosine Drugs 0.000 claims abstract description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 9
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 9
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 9
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 8
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 8
- 235000004279 alanine Nutrition 0.000 claims abstract description 8
- 229960004242 dronabinol Drugs 0.000 claims description 103
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 91
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 79
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 27
- ZMFWTUBNIJBJDB-UHFFFAOYSA-N 6-hydroxy-2-methylquinoline-4-carboxylic acid Chemical class C1=C(O)C=CC2=NC(C)=CC(C(O)=O)=C21 ZMFWTUBNIJBJDB-UHFFFAOYSA-N 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 19
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 14
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 150000003862 amino acid derivatives Chemical class 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 230000002378 acidificating effect Effects 0.000 claims description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- CAEWJEXPFKNBQL-UHFFFAOYSA-N prop-2-enyl carbonochloridate Chemical compound ClC(=O)OCC=C CAEWJEXPFKNBQL-UHFFFAOYSA-N 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 5
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 3
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims description 2
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 claims description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 12
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 6
- ROGOFPXAUZXIIO-UHFFFAOYSA-N C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.C1(=CC=CC=C1)[SiH3] Chemical compound C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.C1(=CC=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.C1(=CC=CC=C1)[SiH3] ROGOFPXAUZXIIO-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000003937 drug carrier Substances 0.000 abstract description 3
- RBHLFWNKEWLHBP-UHFFFAOYSA-N 4-(4-aminophenyl)butanoic acid Chemical compound NC1=CC=C(CCCC(O)=O)C=C1 RBHLFWNKEWLHBP-UHFFFAOYSA-N 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- 229940002612 prodrug Drugs 0.000 description 43
- 239000000651 prodrug Substances 0.000 description 43
- 239000000047 product Substances 0.000 description 30
- 229940079593 drug Drugs 0.000 description 19
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 18
- 239000000126 substance Substances 0.000 description 16
- GJHFAHVMZHRUFR-UHFFFAOYSA-N 3,4-dimethylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1C GJHFAHVMZHRUFR-UHFFFAOYSA-N 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 238000004949 mass spectrometry Methods 0.000 description 11
- 238000010183 spectrum analysis Methods 0.000 description 11
- 229940071089 sarcosinate Drugs 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-M valinate Chemical compound CC(C)C(N)C([O-])=O KZSNJWFQEVHDMF-UHFFFAOYSA-M 0.000 description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-M leucinate Chemical compound CC(C)CC(N)C([O-])=O ROHFNLRQFUQHCH-UHFFFAOYSA-M 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 230000035699 permeability Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-M tryptophanate Chemical compound C1=CC=C2C(CC(N)C([O-])=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-M 0.000 description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000004611 spectroscopical analysis Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000012384 transportation and delivery Methods 0.000 description 6
- 244000025254 Cannabis sativa Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 229930003827 cannabinoid Natural products 0.000 description 5
- 239000003557 cannabinoid Substances 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 238000001212 derivatisation Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 4
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 4
- 208000008238 Muscle Spasticity Diseases 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940065144 cannabinoids Drugs 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000018198 spasticity Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 229960004150 aciclovir Drugs 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 238000010205 computational analysis Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 150000002634 lipophilic molecules Chemical class 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-L tyrosinate(2-) Chemical compound [O-]C(=O)C(N)CC1=CC=C([O-])C=C1 OUYCCCASQSFEME-UHFFFAOYSA-L 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- YCBKSSAWEUDACY-IAGOWNOFSA-N 11-hydroxy-Delta(9)-tetrahydrocannabinol Chemical compound C1=C(CO)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 YCBKSSAWEUDACY-IAGOWNOFSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000010399 Wasting Syndrome Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 2
- 229960000210 nalidixic acid Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000025889 stromal keratitis Diseases 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- AALXZHPCKJILAZ-UHFFFAOYSA-N (4-propan-2-ylphenyl)methyl 2-hydroxybenzoate Chemical compound C1=CC(C(C)C)=CC=C1COC(=O)C1=CC=CC=C1O AALXZHPCKJILAZ-UHFFFAOYSA-N 0.000 description 1
- ZNJRONVKWRHYBF-UHFFFAOYSA-N 2-[2-[2-(1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-7-yl)ethenyl]-6-methylpyran-4-ylidene]propanedinitrile Chemical compound O1C(C)=CC(=C(C#N)C#N)C=C1C=CC1=CC(CCCN2CCC3)=C2C3=C1 ZNJRONVKWRHYBF-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- YVOODUUYDJKFDY-RTBURBONSA-N 4-[[(6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-yl]oxy]-4-oxobutanoic acid Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(OC(=O)CCC(O)=O)=C3[C@@H]21 YVOODUUYDJKFDY-RTBURBONSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000001733 Basic Amino Acid Transport Systems Human genes 0.000 description 1
- 108010015087 Basic Amino Acid Transport Systems Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000012106 Neutral Amino Acid Transport Systems Human genes 0.000 description 1
- 108010036505 Neutral Amino Acid Transport Systems Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010043521 Throat irritation Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000015107 ale Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 102000017941 granulin Human genes 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000010226 intestinal metabolism Effects 0.000 description 1
- 230000002673 intoxicating effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940099262 marinol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- CLKHQWJXESOLCJ-UHFFFAOYSA-N methyl 4-(4-aminophenyl)butanoate Chemical compound COC(=O)CCCC1=CC=C(N)C=C1 CLKHQWJXESOLCJ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004677 mucosal permeability Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 108010082406 peptide permease Proteins 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229940072132 quinolone antibacterials Drugs 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B08—CLEANING
- B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
- B08B13/00—Accessories or details of general applicability for machines or apparatus for cleaning
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B08—CLEANING
- B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
- B08B3/00—Cleaning by methods involving the use or presence of liquid or steam
- B08B3/02—Cleaning by the force of jets or sprays
- B08B3/026—Cleaning by making use of hand-held spray guns; Fluid preparations therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B08—CLEANING
- B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
- B08B2203/00—Details of cleaning machines or methods involving the use or presence of liquid or steam
- B08B2203/02—Details of machines or methods for cleaning by the force of jets or sprays
- B08B2203/0264—Splash guards
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Virology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11016508P | 2008-10-31 | 2008-10-31 | |
| US61/110,165 | 2008-10-31 | ||
| PCT/US2009/062998 WO2010051541A2 (en) | 2008-10-31 | 2009-11-02 | Compositions containing delta-9-thc-amino acid esters and process of preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009308665A1 AU2009308665A1 (en) | 2010-05-06 |
| AU2009308665B2 true AU2009308665B2 (en) | 2015-10-22 |
Family
ID=42129588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009308665A Active AU2009308665B2 (en) | 2008-10-31 | 2009-11-02 | Compositions containing delta-9-THC-amino acid esters and process of preparation |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8809261B2 (enExample) |
| EP (1) | EP2352497B1 (enExample) |
| JP (1) | JP5739344B2 (enExample) |
| AU (1) | AU2009308665B2 (enExample) |
| CA (1) | CA2741862C (enExample) |
| DK (1) | DK2352497T3 (enExample) |
| ES (1) | ES2622582T3 (enExample) |
| HU (1) | HUE032158T2 (enExample) |
| PL (1) | PL2352497T3 (enExample) |
| WO (1) | WO2010051541A2 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160345631A1 (en) | 2005-07-19 | 2016-12-01 | James Monsees | Portable devices for generating an inhalable vapor |
| US8991402B2 (en) | 2007-12-18 | 2015-03-31 | Pax Labs, Inc. | Aerosol devices and methods for inhaling a substance and uses thereof |
| CA2741862C (en) * | 2008-10-31 | 2017-10-17 | Mahmoud A. Elsohly | Compositions containing delta-9-thc-amino acid esters and process of preparation |
| BR112012023421B1 (pt) | 2010-03-17 | 2021-09-14 | Novaliq Gmbh | Composição farmacêutica para tratamento de aumento de pressão intraocular |
| US10517530B2 (en) | 2012-08-28 | 2019-12-31 | Juul Labs, Inc. | Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances |
| CA2997744C (en) | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| CA3142049C (en) | 2012-09-12 | 2023-08-29 | Novaliq Gmbh | Semifluorinated alkane compositions |
| US10653180B2 (en) | 2013-06-14 | 2020-05-19 | Juul Labs, Inc. | Multiple heating elements with separate vaporizable materials in an electric vaporization device |
| US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
| ES2999088T3 (en) | 2013-05-06 | 2025-02-24 | Juul Labs Inc | Nicotine salt formulations for aerosol devices and methods thereof |
| IL295735B2 (en) | 2013-12-05 | 2024-04-01 | Juul Labs Inc | Nicotine liquid formulations for aerosol devices and methods thereof |
| USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
| US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
| US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
| US20160366947A1 (en) | 2013-12-23 | 2016-12-22 | James Monsees | Vaporizer apparatus |
| US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
| USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
| PL3504991T3 (pl) | 2013-12-23 | 2021-08-16 | Juul Labs International Inc. | Systemy urządzeń do odparowywania |
| CA2948851A1 (en) | 2014-05-16 | 2015-11-19 | Pax Labs, Inc. | Systems and methods for aerosolizing a smokeable material |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| US10610512B2 (en) | 2014-06-26 | 2020-04-07 | Island Breeze Systems Ca, Llc | MDI related products and methods of use |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| EP4464356A3 (en) | 2014-12-05 | 2025-01-08 | Juul Labs, Inc. | Calibrated dose control |
| EP3270896A4 (en) * | 2015-03-19 | 2018-09-12 | One World Cannabis Ltd. | Preparations of cannabis emulsions and methods thereof |
| CN105037180B (zh) * | 2015-04-19 | 2017-10-10 | 安徽省逸欣铭医药科技有限公司 | 一种双重作用的中枢性镇痛新化合物、制备方法及用途 |
| EP3297617A4 (en) * | 2015-05-18 | 2019-02-20 | 5071, Inc. | HOMOGENEOUS CANNABIC COMPOSITION AND METHOD FOR THE MANUFACTURE THEREOF |
| CA3176674A1 (en) | 2015-05-18 | 2016-11-24 | 5071, Inc. | Homogenous cannabis compositions and methods of making the same |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| DK3356313T3 (da) | 2015-09-30 | 2020-07-20 | Novaliq Gmbh | 2-perfluorhexyloktan til oftalmisk indgivelse |
| WO2017055454A1 (en) | 2015-09-30 | 2017-04-06 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| AU2017212651B2 (en) | 2016-01-29 | 2020-01-23 | University Of Mississippi | Biologically active cannabidiol analogs |
| EA039727B1 (ru) | 2016-02-11 | 2022-03-04 | Джуул Лэбз, Инк. | Надежно прикрепляющиеся картриджи для испарительных устройств |
| DE202017007467U1 (de) | 2016-02-11 | 2021-12-08 | Juul Labs, Inc. | Befüllbare Verdampferkartusche |
| US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
| US20220087972A9 (en) | 2016-04-15 | 2022-03-24 | Sre Wellness, Inc. | Cannabinoid Compositions |
| CA3021095A1 (en) * | 2016-04-15 | 2017-10-19 | Sre Wellness Inc. | Method of making cannabis oil hydrophiilic using emulsifiers and related cannabinoid compositions |
| EP3442521A4 (en) | 2016-04-15 | 2020-01-01 | SRE Wellness, Inc. | SWEETENERS AND ELIXIRS INFused WITH CANNABIS |
| USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
| CA3027913A1 (en) * | 2016-06-16 | 2017-12-21 | Teewinot Technologies Limited | Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use |
| USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
| USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
| USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
| US11660403B2 (en) | 2016-09-22 | 2023-05-30 | Juul Labs, Inc. | Leak-resistant vaporizer device |
| CN109906085B (zh) | 2016-09-23 | 2024-03-08 | 诺瓦利克有限责任公司 | 含有环孢素的眼用组合物 |
| CA3036313A1 (en) | 2016-09-28 | 2018-04-05 | Novaliq Gmbh | Compositions comprising a cannabinoid receptor binding ligand |
| US11117852B2 (en) | 2017-04-05 | 2021-09-14 | University Of Mississippi | Isolation of pure cannabinoids from Cannabis |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| EP3424494A1 (en) * | 2017-07-07 | 2019-01-09 | SolMic Research GmbH | Stable cannabinoid compositions |
| EP3424493A1 (en) | 2017-07-07 | 2019-01-09 | SolMic Research GmbH | Stable cannabinoid compositions |
| US20190015383A1 (en) * | 2017-07-14 | 2019-01-17 | 5071, Inc. | Cannabinoid compositions and methods of preparation thereof |
| IL272601B2 (en) * | 2017-08-27 | 2025-03-01 | Rhodes Tech Inc | Pharmaceutical compositions for the treatment of ophthalmic conditions |
| USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
| SG11202002640YA (en) | 2017-09-27 | 2020-04-29 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| US11498018B2 (en) * | 2017-11-27 | 2022-11-15 | Vasilios (Bill) Panagiotakopoulos | Extraction and purification of cannabinoid compounds |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| WO2019206956A1 (en) | 2018-04-27 | 2019-10-31 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| MY206642A (en) | 2018-10-12 | 2024-12-30 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US20220000774A1 (en) * | 2018-11-07 | 2022-01-06 | Columbia Care Llc | Suppository formulations having cannabinoid |
| CA3128400A1 (en) * | 2019-02-11 | 2020-08-20 | John R. Chancey | Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disaccharide, or monosaccharide |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| EP3938359A4 (en) * | 2019-03-12 | 2023-09-27 | 6th Wave Innovations Corp. | MOLECULAR EMBOSSED POLYMERS FOR EXTRACTION OF CANNABINOIDS AND USES THEREOF |
| CA3136607A1 (en) * | 2019-04-09 | 2020-10-15 | Powderpost, Inc. | Methods and compositions for use in treatment of cancer without psychoactive effects |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| CN115867533B (zh) | 2020-06-30 | 2024-07-23 | 加拿大瑞安神经科学公司 | 色胺前药 |
| CN116685312A (zh) * | 2020-11-06 | 2023-09-01 | 泽利拉治疗手术私人有限公司 | 大麻素封装技术 |
| US11242330B1 (en) | 2021-02-25 | 2022-02-08 | Acid Neutral Alkaline Laboratory | Organic catalyst and method for preparation of aromatic tricyclic pyrans |
| US11242328B1 (en) | 2021-02-25 | 2022-02-08 | Acid Neutral Alkaline Laboratory | Heterogeneous catalyst and method for preparation of aromatic tricyclic pyrans |
| US11352337B1 (en) * | 2021-06-02 | 2022-06-07 | Acid Neutral Alkaline Laboratory | Zeolite catalyst and method for preparation of aromatic tricyclic pyrans |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB313977A (en) * | 1927-12-21 | 1929-06-21 | British United Shoe Machinery | Improvements in or relating to boot or shoe sewing machines or methods of making boots or shoes by the use thereof |
| US4933363A (en) * | 1988-08-16 | 1990-06-12 | Elsohly Mahmoud A | Method for effecting systemic delivery of delta-9-tetrahydrocannabinol |
| WO2008134668A2 (en) * | 2007-04-27 | 2008-11-06 | Alexza Pharmaceuticals, Inc. | Heat-labile prodrugs |
| WO2009073633A1 (en) * | 2007-11-30 | 2009-06-11 | Alltranz Inc. | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5518709B2 (enExample) | 1970-02-13 | 1980-05-21 | ||
| US6040298A (en) * | 1992-12-23 | 2000-03-21 | Oclassen Pharmaceuticals, Inc. | Methods for treatment with compositions effective against acyclovir-resistant strains of herpes viruses |
| US5389375A (en) | 1993-05-21 | 1995-02-14 | University Of Mississippi | Stable suppository formulations effecting bioavailability of Δ9 -thc |
| US5631297A (en) * | 1994-07-11 | 1997-05-20 | Pate; David W. | Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same |
| US6008383A (en) * | 1998-10-26 | 1999-12-28 | University Of Mississippi | Method of preparing delta-9-tetrahydrocannabinol esters |
| US20060078955A1 (en) * | 2004-10-13 | 2006-04-13 | Lin-Zhi International | Method for retrieving delta9-THC from oral fluid |
| WO2006050421A1 (en) | 2004-11-02 | 2006-05-11 | New River Pharmaceuticals Inc. | Prodrugs of ribavirin with improved hepatic delivery |
| CA2659775A1 (en) * | 2006-08-04 | 2008-02-14 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
| CA2990445C (en) * | 2007-08-21 | 2020-05-05 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| US20100303883A1 (en) * | 2007-10-17 | 2010-12-02 | Axxia Pharmaceuticals, Llc | Polymeric drug delivery systems and thermoplastic extrusion processes for producing such systems |
| US20090169629A1 (en) * | 2008-01-02 | 2009-07-02 | Novagali Pharma Sa | Micellar compositions with ophthalmic applications |
| EP2151234A1 (en) * | 2008-07-28 | 2010-02-10 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion |
| CA2741862C (en) * | 2008-10-31 | 2017-10-17 | Mahmoud A. Elsohly | Compositions containing delta-9-thc-amino acid esters and process of preparation |
-
2009
- 2009-11-02 CA CA2741862A patent/CA2741862C/en active Active
- 2009-11-02 EP EP09824226.6A patent/EP2352497B1/en active Active
- 2009-11-02 ES ES09824226.6T patent/ES2622582T3/es active Active
- 2009-11-02 WO PCT/US2009/062998 patent/WO2010051541A2/en not_active Ceased
- 2009-11-02 JP JP2011534860A patent/JP5739344B2/ja active Active
- 2009-11-02 HU HUE09824226A patent/HUE032158T2/en unknown
- 2009-11-02 DK DK09824226.6T patent/DK2352497T3/en active
- 2009-11-02 US US13/126,606 patent/US8809261B2/en active Active
- 2009-11-02 AU AU2009308665A patent/AU2009308665B2/en active Active
- 2009-11-02 PL PL09824226T patent/PL2352497T3/pl unknown
-
2014
- 2014-08-18 US US14/462,482 patent/US9630941B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB313977A (en) * | 1927-12-21 | 1929-06-21 | British United Shoe Machinery | Improvements in or relating to boot or shoe sewing machines or methods of making boots or shoes by the use thereof |
| US4933363A (en) * | 1988-08-16 | 1990-06-12 | Elsohly Mahmoud A | Method for effecting systemic delivery of delta-9-tetrahydrocannabinol |
| WO2008134668A2 (en) * | 2007-04-27 | 2008-11-06 | Alexza Pharmaceuticals, Inc. | Heat-labile prodrugs |
| WO2009073633A1 (en) * | 2007-11-30 | 2009-06-11 | Alltranz Inc. | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same |
Non-Patent Citations (2)
| Title |
|---|
| ELSOHLY, M.A., et al., Pharmacology Biochemistry & Behavior, 1991, vol. 40, pp. 497-502 * |
| ZITCO, B.A., et al., Science, 1972, vol. 177. pp. 442-444 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010051541A2 (en) | 2010-05-06 |
| EP2352497A4 (en) | 2012-08-01 |
| US8809261B2 (en) | 2014-08-19 |
| ES2622582T3 (es) | 2017-07-06 |
| US9630941B2 (en) | 2017-04-25 |
| JP2012507568A (ja) | 2012-03-29 |
| WO2010051541A3 (en) | 2010-07-08 |
| AU2009308665A1 (en) | 2010-05-06 |
| CA2741862C (en) | 2017-10-17 |
| PL2352497T3 (pl) | 2017-08-31 |
| US20150045282A1 (en) | 2015-02-12 |
| CA2741862A1 (en) | 2010-05-06 |
| JP5739344B2 (ja) | 2015-06-24 |
| EP2352497A2 (en) | 2011-08-10 |
| US20110275555A1 (en) | 2011-11-10 |
| DK2352497T3 (en) | 2017-04-03 |
| EP2352497B1 (en) | 2017-02-22 |
| HK1158517A1 (en) | 2012-07-20 |
| HUE032158T2 (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009308665B2 (en) | Compositions containing delta-9-THC-amino acid esters and process of preparation | |
| EP2841066B1 (en) | Anti-influenza agent conjugated to anti-inflammatory agent | |
| JP5372751B2 (ja) | Ａｚａ−ペプチドプロテアーゼ阻害剤 | |
| RU2623426C2 (ru) | Способ получения блок-сополимера | |
| BRPI0611435A2 (pt) | derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos | |
| CN101624376B (zh) | 取代酰肼类化合物及其应用 | |
| CN103387601B (zh) | 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途 | |
| CN115385875B (zh) | 一类紫杉醇衍生物及其制备方法和用途 | |
| CN103304573B (zh) | 石蒜碱类化合物在制备抗肿瘤药物的应用 | |
| US20050220753A1 (en) | Hydrophilic polymers-flavoids conjugates and pharmaceutical compositions comprising them | |
| CN113773259A (zh) | 病毒主蛋白酶抑制剂及其制备方法和用途 | |
| HK1158517B (en) | Process of preparation of delta-9-thc-amino acid esters | |
| US20070072802A1 (en) | Peptide nucleic acid based guanidinium compounds | |
| CN117384136A (zh) | 一种no供体型抗真菌化合物及其制法和应用 | |
| CN109420179B (zh) | 多烯紫杉烷靶向前药及其抗结肠癌药用用途 | |
| CN109896986A (zh) | 木脂素类天然产物4-o-甲基三白草醇的结构简化物，其制法和其药物组合物与用途 | |
| CN110922450B (zh) | Psma激活式抗肿瘤前药cpt-x及其制备方法和应用 | |
| JPH0660168B2 (ja) | ０―置換フマギロール誘導体 | |
| HK40086425A (zh) | 秋水仙碱衍生物的制备方法及其用途 | |
| CN120040321A (zh) | 基于疏水标签技术的神经氨酸酶抑制剂及其制备方法、衍生物、药物组合物和应用 | |
| KR20220068805A (ko) | 신규한 글루코스 유도체 | |
| CN118356506A (zh) | 去唾液酸糖蛋白受体配体与细胞毒素的偶联物及其应用 | |
| WO2013184780A1 (en) | Novel iminosugars and their applications | |
| CN111057127A (zh) | Psma激活式抗肿瘤前药cpt-x及其制备方法和应用 | |
| CN109422759A (zh) | 小分子修饰的紫杉烷类水溶性前药及其药用用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ELSOHLY, MAHMOUD A.; GUL, WASEEM; REPKA, MICHAEL A. AND MAJUMDAR, SOUMYAJIT |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: THE UNIVERSITY OF MISSISSIPPI Free format text: FORMER APPLICANT(S): ELSOHLY LABORATORIES, INCORPORATED |
|
| FGA | Letters patent sealed or granted (standard patent) |